Skip to content
10-Q/A

Quarterly Report

Zander Therapeutics, Inc

0001607062-19-000295

← back to feed
Filed
Jun 28, 2019 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2019 · Dec 31, 2018 6.03M sh
Operating Cash Flow Q2 2019 · Dec 31, 2018 −$713.97K
Operating Cash Flow restated Q2 2019 · Dec 31, 2017 −$257.11K
Cash And Equivalents Q2 2019 · Dec 31, 2018 $71.35K
Cash And Equivalents Q2 2019 · Jun 30, 2018 $370.31K
Cash And Equivalents Q2 2019 · Dec 31, 2017 $721.24K
Cash And Equivalents Q2 2019 · Jun 30, 2017 $96.01K
Net Income restated Q2 2019 · Dec 31, 2018 −$1.14M
Net Income Q2 2019 · Dec 31, 2017 −$166.64K
Net Income Q2 2019 · Dec 31, 2017 −$293.86K
Sga Expense Q2 2019 · Dec 31, 2017 $20.98K
Sga Expense Q2 2019 · Dec 31, 2017 $42.14K
Rd Expense Q2 2019 · Dec 31, 2017 $27.43K
Rd Expense Q2 2019 · Dec 31, 2017 $55K
Operating Income Q2 2019 · Dec 31, 2017 −$162.77K
Operating Income Q2 2019 · Dec 31, 2017 −$285.17K